The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000410358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/03/2026
Date registered
Help: Date registered
2/04/2026
Date last updated
Help: Date last updated
2/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
2/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The efficacy of vitamin B12 in reducing ocular signs and symptoms of dry eye disease
Scientific title
The efficacy of vitamin B12 in ocular signs and symptoms of dry eye disease in participants 18 and over
Additional trial identifiers [1] 314923 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Dry eye disease 338243 0
Condition category
Condition code
Eye 334522 334522 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Oral vitamin B12 supplement:
-Mecobalamin 1000 microgram, once daily.
-3 months administration.
-Compliance will be monitored by counting the dispensed and returned capsules and bottles of capsules, as well as by questioning the participants at each visit. For remote compliance control participants will be asked to use the redcap platform.
Intervention code [1] 331527 0
Treatment: Drugs
Description of the comparator or control
Placebo. capsules of Maltodextrin will be used as vitamin B12 supplements placebo
Control group
Placebo

Outcomes
Primary outcome [1] 342199 0
Dry eye symptoms. This will be assessed as a composite outcome.
Timepoint [1] 342199 0
Baseline, 1.5 month±7 days from visit 1 (primary timepoint), 3 months ± 7 days from visit 1 (primary timepoint)
Secondary outcome [1] 450270 0
Change in corneal innervation, Change in immune cell population numbers. This will be assessed as a composite outcome.
Timepoint [1] 450270 0
baseline and 3 months ± 7 days from visit 1 (primary timepoint).
Secondary outcome [2] 450271 0
Vitamin B12 serum level
Timepoint [2] 450271 0
baseline and 3 months ± 7 days from visit 1 (primary timepoint).
Secondary outcome [3] 459278 0
Dry eye signs. This will be assessed as a composite outcome.
Timepoint [3] 459278 0
1
Secondary outcome [4] 459279 0
Tear inflammatory biomarkers. This will be assessed as a composite outcome.
Timepoint [4] 459279 0
Baseline, 1 month and 4 months from baseline.

Eligibility
Key inclusion criteria
• Be able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
• No previous vitamin B12 commercial supplements in the last three months
• Currently have been diagnosed with dry eye disease.
• Be at least 18 years old
• Be willing to comply with the consuming supplement product and clinical trial visit schedule.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Currently taking vitamin B12 commercial supplements. Participants will be advised not to change their diet for the duration of the study.
• Eye surgery within 12 weeks immediately prior to enrolment for this trial
• Previous corneal refractive surgery
• Active corneal infection or any active ocular disease such as iritis, corneal oedema or corneal dystrophies, including anterior membrane dystrophy.
• Any current ocular injury
• Be currently enrolled in another clinical trial or have participated in a clinical trial within the previous 2 weeks.
• Pregnant or lactating

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Dry eye disease-diagnosed participants will be divided randomly through a web-based system into two groups, either supplemented with oral vitamin B12 or placebo (maltodextrin) intake. The randomisation schedule will be provided to a pharmacist who will repackage study supplements with similar characteristics into identical opaque containers. In this case participants and study personnel will be masked to participant allocation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computerised sequence generation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis
Statistical analysis is planned to commence on completion of trial monitoring and the submission of the data analysis request form. Any analysis will be conducted as described in this section, unless a documented request is received from the Sponsor and approved by the trial PI.
Data stored in relational databases will be imported into SPSS / STATA software for statistical purposes. Data will be investigated for quality using range checks and frequency distribution. Underlying distributions of variables will be tested. In general, variables measured on an interval scale with a sufficiently large sample size will be considered to follow a normal distribution. Outputs from the statistical analysis such as statistical tables will be copied over to Excel. Graphs will generally not be created from the statistical software. All statistical results will be reported in Excel format. General Linear Mixed Model will be used to look for differences between the groups and between visits for primary outcome measures OSDI and secondary outcome measures TBUT and staining, as well as all other outcome measures

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 319485 0
University
Name [1] 319485 0
University of New South Wales Sydney
Country [1] 319485 0
Australia
Primary sponsor type
University
Name
University of New South Wales Sydney
Address
Country
Australia
Secondary sponsor category [1] 322073 0
None
Name [1] 322073 0
Address [1] 322073 0
Country [1] 322073 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318057 0
The University of New South Wales Research Ethics Committee A
Ethics committee address [1] 318057 0
Ethics committee country [1] 318057 0
Australia
Date submitted for ethics approval [1] 318057 0
31/08/2025
Approval date [1] 318057 0
27/02/2026
Ethics approval number [1] 318057 0
iRECS9103

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142986 0
A/Prof Maria Markoulli
Address 142986 0
School of optometry and vision science, Gate 14, Barker St, Level 3, Rupert Myers Building, UNSW Sydney Kensington, NSW, 2052
Country 142986 0
Australia
Phone 142986 0
+61 290657355
Fax 142986 0
Email 142986 0
Contact person for public queries
Name 142987 0
Hamidreza Heidari
Address 142987 0
School of optometry and vision science, Gate 14, Barker St, Level 3, Rupert Myers Building, UNSW Sydney Kensington, NSW, 2052
Country 142987 0
Australia
Phone 142987 0
+61499271913
Fax 142987 0
Email 142987 0
Contact person for scientific queries
Name 142988 0
Maria Markoulli
Address 142988 0
School of optometry and vision science, Gate 14, Barker St, Level 3, Rupert Myers Building, UNSW Sydney Kensington, NSW, 2052
Country 142988 0
Australia
Phone 142988 0
+61 290657355
Fax 142988 0
Email 142988 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval  [email protected]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.